Iradimed Co (IRMD) is a publicly traded medical devices business based in the US. In the week up to 13 September IRadimed shares plunged 8.58% to a closing position of $44.2. However, over the last 12 months, IRadimed's share price has risen by 3.56% from $29.5. IRadimed is listed on the NASDAQ and employs 123 staff. All prices are listed in US Dollars.
Best for
0% commission
Best for
Beginner investments
Best for
Beginners
BEST FOR
US shares
Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.
| Platform | Customer feedback | Monthly fee | Min. initial deposit | Trading fee estimate | |
|---|---|---|---|---|---|
|
★★★★★ | £0 | $50 | £2.52 £505.92 total |
Capital at risk |
|
★★★★★ | £0 - £9.99 | No minimum | £2.97 £506.37 total |
Capital at risk |
|
★★★★★ | £0 | £250 | £10.80 £514.20 total |
Capital at risk |
 |
Not yet rated | £0 | No minimum | £2.52 £505.92 total |
Capital at risk |
|
★★★★★ | £0 - £10 | No minimum | £2.52 £505.92 total |
Capital at risk |
 |
★★★★★ | £0 | £1 | £16.98 £520.39 total |
Capital at risk |
Full comparison of share dealing platforms
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Only you can make the decision on the time to leap. The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.
Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value. Check out the IRadimed P/E ratio, PEG ratio and EBITDA
IRadimed's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 39x. In other words, IRadimed shares trade at around 39x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
However, IRadimed's P/E ratio is best considered in relation to those of others within the medical devices industry or those of similar companies.
IRadimed's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 4.46. Higher PEG ratios such as this can be interpreted as meaning the shares offer worse value given the current rate of growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into IRadimed's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider IRadimed's PEG ratio in relation to those of similar companies.
IRadimed's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $17.5 million (£0.0 million).
The EBITDA is a measure of a IRadimed's overall financial performance and is widely used to measure a its profitability.
To put that into context you can compare it against similar companies.
Join 50,000 subscribers who are notified about expert share tips. Plus a chance to win £500!
By signing up you agree to receive emails from Finder and to the privacy policy and terms & conditions.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Ever wondered how to buy shares in Kyocera? We explain how and compare a range of providers that can give you access to many brands, including Kyocera.
Ever wondered how to buy shares in General Finance? We explain how and compare a range of providers that can give you access to many brands, including General Finance.
Ever wondered how to buy shares in Baringsorate Investors? We explain how and compare a range of providers that can give you access to many brands, including Baringsorate Investors.
Ever wondered how to buy shares in 1st Source? We explain how and compare a range of providers that can give you access to many brands, including 1st Source.
Ever wondered how to buy shares in Eargo? We explain how and compare a range of providers that can give you access to many brands, including Eargo.
Ever wondered how to buy shares in MediaAlpha? We explain how and compare a range of providers that can give you access to many brands, including MediaAlpha.
Ever wondered how to buy shares in Casper Sleep? We explain how and compare a range of providers that can give you access to many brands, including Casper Sleep.
Ever wondered how to buy shares in X Financial? We explain how and compare a range of providers that can give you access to many brands, including X Financial.
Ever wondered how to buy shares in Capital City Bank Group? We explain how and compare a range of providers that can give you access to many brands, including Capital City Bank Group.
Ever wondered how to buy shares in Genpact? We explain how and compare a range of providers that can give you access to many brands, including Genpact.